Samer Choucair: Sandoz”s Localization of Specialty Pharmaceutical Manufacturing in Saudi Arabia Strengthens Drug Security and Creates New Investment Opportunities
Investment entrepreneur Samer Choucair stated that the announcement by Swiss pharmaceutical company Sandoz, in partnership with Tabuk Pharmaceuticals and under the sponsorship of the Local Content and Government Procurement Authority, to launch the first phase of a project to localize the manufacturing and packaging of high-value specialty medicines in Saudi Arabia during the first quarter of 2027 marks a significant milestone in the development of the Kingdom's pharmaceutical industry. He said the initiative demonstrates Saudi Arabia's successful transition from an import-dependent model to building advanced domestic manufacturing capabilities.
Choucair explained that the project will initially focus on producing immunosuppressant medications for organ transplant patients, alongside critical-care antibiotics. Production capacity is expected to expand by the end of 2028, enabling the supply of treatments for approximately two million patients.
He added that the initiative comes after Sandoz's five decades of presence in the Saudi market and three years after establishing its regional Middle East headquarters in the Kingdom, reflecting the company's strategic shift toward relocating part of its pharmaceutical value chain to Saudi Arabia.
Drug Market Growth Supports Localization Opportunities
Samer Choucair noted that Saudi Arabia's pharmaceutical market, valued at approximately $15 billion, is one of the largest healthcare markets in the region, while annual spending on biologic medicines is estimated at around $5 billion.
He added that biosimilar medicines offer cost savings of between 30% and 40% compared with original biologic therapies, making local production an important tool for improving healthcare spending efficiency and strengthening the long-term sustainability of the healthcare system.
Choucair pointed out that Sandoz, which generated net global sales of $11.1 billion in 2025, maintains a portfolio of approximately 1,300 medicines, including nearly 200 products already available in Saudi Arabia, providing the company with a solid foundation for further expansion within the Kingdom.
Technology Transfer Enhances Investment Appeal
Samer Choucair explained that the project extends well beyond local manufacturing, incorporating technology transfer, operational knowledge sharing, and the training of Saudi professionals according to international standards.
He said this represents a significant evolution beyond traditional supply agreements by focusing on building a sophisticated domestic pharmaceutical industry capable of creating sustainable added value.
Samer Choucair said: "This partnership goes far beyond conventional commercial agreements by delivering genuine technology transfer and operational expertise. That significantly enhances the attractiveness of investment in Saudi Arabia's healthcare ecosystem while creating projects capable of generating lasting economic and social value."
Specialty Medicines to Drive the Next Growth Phase
Choucair noted that the project focuses on high-value specialty medicines, a segment experiencing continuous growth alongside the expansion of Saudi Arabia's healthcare services.
He added that Sandoz is also evaluating the localization of biologic medicine manufacturing despite its technical complexity, a move that would strengthen pharmaceutical security while reducing treatment costs over the long term.
According to Choucair, this direction aligns with global trends toward expanding biosimilar production and positions Saudi Arabia to meet domestic demand while creating future export opportunities.
Strategic Partnership Strengthens Competitiveness
Samer Choucair explained that Sandoz benefits from a significant competitive advantage through its five-decade presence in the Saudi market and its regional headquarters in Riyadh.
He added that Tabuk Pharmaceuticals was selected because it is the Kingdom's largest privately owned pharmaceutical company, supported by advanced manufacturing infrastructure and extensive production expertise.
Choucair also highlighted that support from the Local Content and Government Procurement Authority provides the project with strong regulatory momentum while increasing its ability to benefit from government procurement programs and localization initiatives.
Vision 2030 Accelerates Pharmaceutical Industry Growth
Choucair emphasized that the project aligns directly with the objectives of Saudi Vision 2030, particularly efforts to diversify the economy and reduce reliance on imports in strategic industries.
He added that technology transfer and the development of local industrial capabilities will create highly skilled employment opportunities while building a sustainable pharmaceutical sector that supports the non-oil economy and strengthens supply chain resilience following the global disruptions experienced in recent years.
Saudi Arabia Positioned to Become a Regional Hub
Samer Choucair stated that completing the project's expansion phases by 2028 will allow Sandoz to meet domestic demand before expanding exports to regional markets.
He said this strategy reinforces Saudi Arabia's position as a regional hub for pharmaceutical manufacturing and biotechnology and could serve as a model for other Gulf Cooperation Council countries seeking to strengthen their own pharmaceutical industries.
Execution Challenges Require Close Monitoring
Choucair cautioned that despite the project's importance, it faces several implementation challenges, including maintaining the timeline for technology transfer, securing the necessary approvals from the Saudi Food and Drug Authority, and managing the technical complexity of advanced pharmaceutical manufacturing processes that could affect project schedules and costs.
Samer Choucair said: "The success of projects like this depends on the precise execution of technology transfer and full compliance with international standards. Investors should closely monitor operational risks throughout the implementation process."
Long-Term Investment Opportunities
Choucair said the initiative provides Sandoz with an opportunity to strengthen its presence in one of the region's fastest-growing pharmaceutical markets. The company currently holds approximately 1.5% of the Saudi pharmaceutical market and aims to double its market share over the next five years.
He added that policies supporting domestic manufacturing, combined with the development of national talent, will establish a strong platform for future growth while reducing dependence on imported medicines.
Samer Choucair said: "As spending on biologic medicines continues to rise and biosimilars deliver substantial cost savings, local manufacturing represents an attractive investment opportunity for institutions targeting healthcare growth across emerging markets."
Outlook for Investors
Choucair encouraged investors to closely monitor the project's upcoming milestones, particularly regulatory approvals and pilot production activities during 2026 and 2027, while also following Sandoz's broader expansion strategy across emerging markets.
He added that healthcare and pharmaceutical manufacturing will remain among the sectors most likely to attract investment in the coming years, supported by the continued implementation of Saudi Vision 2030.
Advanced Pharmaceutical Manufacturing
Concluding his remarks, Samer Choucair said the Sandoz project represents a practical example of how Saudi industrial policy is being transformed into tangible investment opportunities. He emphasized that partnerships combining global expertise with local execution have become one of the most important drivers of Saudi Arabia's economic growth.
He added that continued foreign direct investment in advanced pharmaceutical manufacturing will support the development of a more sustainable healthcare sector, strengthen Saudi Arabia's position as a regional hub for life sciences, and create long-term investment opportunities aligned with the Kingdom's economic diversification strategy and Vision 2030.